Suprane

Quick links to important sections

Suprane

Selected form

Method of action: Anesthetic

Treatment option: Anesthesia, Laryngospasm, Surgery

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suprane

Property Description
Active ingredient Desflurane
Form Inhalation Solution (Volatile Liquid)
Pharmacological class General Anesthetic, Volatile Anesthetic
Common use Inducing and maintaining general anesthesia for surgery
Origin Synthetic (Halogenated Ether)

What Type of Medicine is Suprane (Desflurane)?

Suprane is the trade name for the active ingredient Desflurane, a potent, synthetic General Anesthetic agent used to induce and sustain a controlled state of unconsciousness during surgical and medical procedures. It is classified pharmacologically as a volatile anesthetic and chemically as a halogenated ether. The medicine is a single-ingredient product, consisting solely of Desflurane, which exists as a pure volatile liquid at room temperature. Its specialized chemical structure, 1,2,2,2-tetrafluoroethyl difluoromethyl ether, dictates its delivery as an Inhalation Solution via a dedicated, calibrated vaporizing system into the lungs, which is necessary for agents of this class.


What is the General Purpose of Suprane?

The primary purpose of Desflurane is to provide the reliable, controlled, and reversible central nervous system depression required during major medical procedures. The drug is clinically recognized for its utility in both the induction and maintenance of anesthesia, making it a versatile component in operating room settings. The agent achieves this by creating a state of unconsciousness and providing a global sensory blockade, ensuring the patient is completely unaware of pain or sensory input throughout the operation. Its role is strictly foundational, ensuring patient stillness and safety during interventions that require a high degree of control.


Why is Desflurane Considered a Rapid-Acting Agent?

Desflurane is known for being a rapid-acting agent due to an intrinsic property of its synthetic composition: its very low blood solubility. This chemical feature is crucial because it allows the anesthetic to reach the brain quickly to initiate its effects, and, significantly, to be eliminated rapidly from the body via exhalation once administration is stopped. This mechanism translates to a notably rapid onset of anesthesia and, more advantageously, a quick emergence and rapid recovery profile, which is a differentiating factor often leveraged in efficient surgical settings.

What side effects are possible with Suprane?

Possible Side Effects and Safety Information

The safety profile of Desflurane is defined by officially classified adverse reactions grouped by frequency and physiological system, according to governmental regulatory documents. The most frequently reported adverse effects involve the cardiovascular, respiratory, and gastrointestinal systems.

Adverse Reactions by Frequency

Classification Examples of Officially Listed Reactions
Very Common Nausea, Vomiting, Salivary hypersecretion, Coughing, Breath holding.
Common Tachycardia, Hypertension, Laryngospasm, Headache, Nodal arrhythmia, Apnea.
Uncommon Agitation, Dizziness, Myalgia.

Serious Adverse Reactions

The label documents specific serious adverse reactions, which are typically rare but clinically critical. These include Malignant Hyperthermia (MH), a potentially fatal hypermetabolic state in susceptible individuals, and Fatal Hepatic Necrosis, a severe form of liver injury. Additionally, there is a documented risk of severe Perioperative Hyperkalemia which has been associated with cardiac arrhythmias and death, particularly in children with latent neuromuscular disease.

Population-Specific Safety Constraints

Official safety information outlines constraints for specific groups. Desflurane is contraindicated for the induction of anesthesia in non-intubated pediatric patients due to a high incidence of respiratory complications. It is also contraindicated in individuals with a known or suspected susceptibility to MH or a history of moderate-to-severe hepatic dysfunction following previous halogenated anesthetic exposure. The rapid increase of anesthetic concentration may cause a transient increase in heart rate and blood pressure.

Overdose and Emergency Response

Official Overdose Manifestations

Overdose of Suprane (Desflurane) is formally documented in regulatory sources as an excessive deepening of the anesthetic state resulting from administering an excessive concentration of the agent. This condition affects the respiratory and circulatory systems. The recognized clinical signs include profound respiratory depression (hypoventilation) and severe hypotension, which are dose-related effects. These manifestations can escalate to life-threatening outcomes such as circulatory depression, hypoxia, and potentially cardiac arrest. Regulatory documents note that the required agent concentration is adjusted based on patient age, as the dose needed to prevent excessive anesthetic depth decreases in older patients.


Emergency Action and Supportive Management

Regulatory statements mandate that upon suspicion of overdose, the first required action is the immediate discontinuation of the anesthetic agent. Seek immediate medical attention is required for persistent or severe symptoms, and resuscitation facilities must be immediately available. Management must be symptomatic and supportive, including the establishment of a patent airway and instituting assisted or controlled ventilation with 100% oxygen. The official labeling confirms that no specific antagonist is known for Desflurane overdose.

Therapeutic Uses of Suprane

What Suprane Treats: Main Uses and Benefits

Suprane is commonly used to establish and maintain general anesthesia in adults undergoing major surgical procedures, and is relevant in contexts marked by increased discomfort or tension. Desflurane is indicated for the induction and maintenance of anesthesia in adults, and for maintenance in pediatric patients.

This anesthetic application helps address groups of symptoms that may become intense or disruptive, namely symptoms that interfere with daily functioning, such as awareness, pain sensation, and uncontrolled body movement during the operation. This application contributes to easing the overall symptom load during major procedures by addressing awareness and assisting with body movement during the procedure.

The medication's rapid clearance profile is often applied in clinical settings that involve acute or unstable symptom patterns, particularly in outpatient surgery where short-term symptomatic assistance is needed for recovery, or in specialized procedures. For patients living with obesity, the faster elimination may assist with maintaining a sense of stability when symptoms of systemic imbalance are more noticeable upon emergence.

Quick Fact: Relief for Awareness and Pain Sensation
This volatile anesthetic plays a role in managing distressing manifestations by addressing symptoms related to heightened physiological activity during the procedure.

Eligibility and Restrictions for Use

Who can and cannot use Suprane?

The official regulatory profile for Suprane (Desflurane) establishes clear eligibility rules based on patient status, age, and medical history.

Contraindicated Populations

Use is strictly contraindicated in patients with a known or suspected genetic susceptibility to malignant hyperthermia, a history of moderate to severe hepatic dysfunction following previous halogenated anesthetic exposure, or a known sensitivity to the medicine. General anesthesia itself is also a contraindication for using the drug.

Age- and Procedure-Based Eligibility

Suprane is indicated for both induction and maintenance of general anesthesia in adults. Age imposes significant restrictions in pediatric patients: the medicine is contraindicated for inhalation induction in all children due to the risk of respiratory events. For children, it is approved only for maintenance following intubation with another agent, and is not approved for maintenance in non-intubated children.

Conditional Use and Special Groups

Specific restrictions apply to comorbidities: the medicine must not be used as the sole induction agent in patients with coronary artery disease. Caution is required for individuals with neuromuscular diseases or those with asthma. Regulatory documents state that use is not indicated during pregnancy or lactation. Use is acceptable in patients with chronic renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Suprane (Desflurane) is defined primarily by its effects on the central nervous system and neuromuscular function, reflecting its minimal systemic metabolism as a volatile anesthetic.

Documented Pharmacodynamic Interactions

The co-administration of certain medicinal products is documented to result in significant additive effects:

  • Opioids, Benzodiazepines, and Nitrous Oxide (N₂O): Co-use with these central nervous system depressants produces an additive pharmacodynamic effect, formally documented as decreasing the Minimum Alveolar Concentration (MAC) required for anesthesia.
  • Neuromuscular Blocking Agents (NMBAs): Desflurane is documented to potentiate (enhance) the effect of non-depolarizing NMBAs, requiring a reduction in the dosage of the blocking agent during the maintenance phase of anesthesia.

Other Official Restrictions and Interactions

Interaction Type Official Regulatory Statement
Metabolic Potential Desflurane undergoes negligible biotransformation, indicating a low potential for clinically significant Cytochrome P450 (CYP)-mediated interactions.
Procedural Restriction The drug can react with desiccated Carbon Dioxide (CO₂) absorbents to produce carbon monoxide; absorbents must be replaced if desiccated prior to administration.
Genetic Contraindication Contraindicated in patients with known or suspected genetic susceptibility to Malignant Hyperthermia (MH), as Desflurane is a formally recognized trigger agent.
Population Note The use of Desflurane in patients with Duchenne Muscular Dystrophy is associated with an increased risk of perioperative hyperkalaemia, particularly when co-administered with succinylcholine.

This information describes how regulatory documents define the product’s interaction constraints, focusing on dose-altering pharmacodynamic patterns and mandatory procedural and genetic restrictions.

Mechanism of Action

Dual Modulation of Central Neurotransmission

Desflurane works primarily by engaging mechanisms that regulate central nervous system (CNS) signaling. It acts by positively modulating the inhibitory GABA A receptor and the Glycine receptor, while simultaneously antagonizing the excitatory NMDA receptor . This dual action creates pervasive neuronal hyperpolarization, a state where nerve cells are severely limited in their ability to transmit signals, resulting in CNS depression across cortical and thalamic pathways.


Rapid Onset via Low Blood Solubility

The drug's mechanism leads to a rapid modulation of pathway activity due to its low blood solubility. This chemical property facilitates the swift movement of the molecule from the lungs into the blood and then into the brain tissue, ensuring quick equilibration at its molecular targets. This process initiates the signaling sequences that quickly produce suppression of motor response to stimuli and facilitates rapid offset of the molecular action once administration is stopped.


Systemic Vascular and Respiratory Depression

Beyond the CNS, Desflurane engages mechanisms that influence core regulatory systems. It causes direct relaxation of peripheral vascular smooth muscle, leading to a dose-dependent reduction in systemic vascular resistance and a decrease in blood pressure. The drug also affects systems where CO2 acts as a mediator, dampening the chemoreceptor reflex to decrease the sensitivity of the respiratory center to elevated carbon dioxide levels.

Dosage and Administration Information

How to Use Suprane (Desflurane)

Suprane is an inhalation solution administered solely via the inhalation route to provide general anesthesia. Its administration is highly specialized and requires continuous, individualized adjustment by personnel trained in anesthesia.


Official Administration Requirements

Feature Official Usage Principle
Route & Form Administered as a vaporized liquid via inhalation only.
Equipment Requires a dedicated, calibrated vaporizer specifically designed for Desflurane due to its physical properties.
Supervision Must be administered only by qualified healthcare professionals in a controlled surgical setting.
Dose Pattern (Adults) Concentration is continuously titrated throughout the procedure. Induction is typically initiated with a starting concentration of 3% vol/vol, followed by an increase to 4%-11% for the induction phase. Maintenance is sustained within a range of approximately 2.5% to 8.5%.
Dose Adjustment The required concentration must be lowered for older adults (MAC decreases with age) and when used with concomitant agents like nitrous oxide (N2O) or opioids.
Pediatric Use Its use is strictly limited to the maintenance of anesthesia in intubated children; inhalation induction is contraindicated in this population.

General Use Protocol

Suprane is administered for a short-term, procedure-specific duration, encompassing the induction and maintenance phases of general anesthesia. The concentration is managed moment-to-moment to achieve the desired effect and is ceased upon the conclusion of the surgical procedure, facilitating rapid elimination of the drug.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Suprane (Desflurane)


Evidence for Anesthesia in Adults and General Surgery

The core research on Desflurane was studied for its use in general anesthesia through Randomized Controlled Trials (RCTs) and systematic reviews that typically explored its profile alongside other anesthetic agents. This research examined its use for both putting patients to sleep (induction) and keeping them asleep (maintenance) during various surgical procedures. Studies monitored several key measurement points related to patient activity or functional status immediately following the procedure, including the time it took for patients to awaken and meet discharge milestones.

Research exploring short-term symptom changes reported patterns related to the measurements of time required for patients to reach early recovery milestones when compared to older, less soluble volatile agents. Specifically, findings describe patterns observed in the studies where measurements of time to open eyes and follow simple commands were tracked and analyzed against pre-defined time intervals. Researchers also contributed to the broader evidence landscape by studying physiological measurements, such as changes in heart rate and blood pressure, during the administration of the agent.

Evidence in Specialized Outpatient and Short-Procedure Settings

This evidence has been studied for Desflurane's use in same-day surgery. Trials examined whether the agent was associated with differences in measurements of outcomes reflecting patient activity or functional status relevant to discharge criteria. These studies focused on episodes where patient-reported symptoms were measured upon emergence, such as drowsiness or disorientation. For this use, the follow-up durations were limited primarily to the hours immediately following the procedure.

Evidence for Maintenance of Anesthesia in Intubated Children

For children, Desflurane was evaluated in trials solely for the maintenance of anesthesia in patients who already have an established airway. It was not studied for the initial induction of anesthesia in any pediatric group. This research examined measurements related to postoperative behavioral activity, such as agitation or delirium scores, and also monitored the measurement of airway events. Due to concerns about airway irritation observed in studies, the use of Desflurane is limited to intubated children and is not indicated for non-intubated children.

Frequently Asked Questions (FAQ)

Common questions about Suprane (FAQ)

Q: Is Suprane the same kind of drug as related drugs I've heard of?

A: Suprane (Desflurane) is classified as a volatile general anesthetic and chemically belongs to a group called halogenated ethers. According to official documents, its structure is similar to the anesthetic isoflurane. The medicine is known for its low blood solubility, which gives it a rapid-acting profile often described as a differentiating factor compared to older, less soluble agents.

Q: Is Suprane a type of pain reliever?

A: Suprane is primarily classified as a general anesthetic, not a pain reliever (analgesic). Its main purpose is to induce and maintain a state of controlled unconsciousness. This state includes a global sensory blockade, which ensures the patient is completely unaware of pain or sensory input during a medical procedure.

Q: How long does the effect of Suprane typically last in the body?

A: Studies and official information indicate that Suprane is a rapid-acting agent due to its low blood solubility, which allows it to be eliminated quickly from the body via exhalation. Because of this, emergence (waking up) from anesthesia following the procedure is often measured in a matter of minutes.

Q: Is it normal to feel a specific sensation (e.g., drowsiness, dizziness) after Suprane treatment?

A: Yes, some residual effects are expected following general anesthesia. The product information documents post-operative experiences that may include drowsiness, dizziness, or headache. Agitation and disorientation have also been observed, particularly in some pediatric patients upon emergence.

Q: Does Suprane cause problems with the liver or kidneys?

A: For the liver, serious adverse reactions like fatal hepatic necrosis and disruption of hepatic function have been reported with halogenated anesthetics, due to official warnings regarding prior liver problems. Regarding the kidneys, Desflurane is structurally resistant to the type of breakdown that causes kidney toxicity and is not generally associated with nephrotoxicity (kidney damage).

Q: Are the side effects of Suprane temporary or do they last a long time?

A: Due to the drug's rapid elimination profile (low blood solubility), common immediate side effects like nausea or coughing are typically temporary. The rapid removal of the agent from the body means that the most common adverse effects experienced immediately following the procedure are generally short-lived.

Q: Can I take my regular medications (e.g., blood pressure pills) while being treated with Suprane?

A: Regulatory information emphasizes that decisions about taking concurrent medications is a matter for individual determination by the anesthesia professional managing the procedure. While the drug is documented to interact strongly with CNS depressants and muscle relaxants, clinical trials did not report significant adverse interactions with many other commonly used pre-anesthetic medications.

Q: Is it safe to use Suprane if I have a history of heart problems?

A: Official documentation describes a need for caution for individuals with certain heart conditions. Specifically, official documents state that Suprane should not be used as the sole agent for induction in patients with coronary artery disease. Rapid increases in concentration may also cause a transient increase in heart rate and blood pressure, and administration is controlled by the anesthesia professional.

Q: What is the official classification of Suprane (e.g., Schedule)?

A: Suprane (Desflurane) is classified as a general anesthetic. Regulatory bodies, such as the US DEA, do not list it as a controlled substance. This status reflects that the drug has no established potential for abuse or diversion.

Q: Does Suprane have a known risk of addiction or dependence?

A: Official regulatory documents indicate that the potential for drug abuse and dependence associated with Desflurane has not been formally studied or established. Consistent with this, the medicine is not classified as a controlled substance.

Q: Are there any foods or drinks that should be avoided when receiving Suprane?

A: The official product information does not document specific interactions with foods or drinks. However, regulatory documents indicate that the use of alcohol, tobacco, or any herbal or non-prescription supplements is a matter for discussion with the healthcare professional prior to the procedure.

Q: What should I tell my healthcare provider about my health history before receiving Suprane?

A: The official documentation describes that health conditions which are listed as contraindications or warnings are important for the professional to know. This includes a history of malignant hyperthermia susceptibility, prior severe liver problems after anesthesia, certain heart conditions (like coronary artery disease), asthma, and neuromuscular diseases.

Q: Is Suprane considered a frequently used drug?

A: Reports from health authorities indicate that while historically common, the use of Desflurane has been declining in some areas. This trend is often associated with the drug's relatively high cost and its environmental impact due to its high Global Warming Potential compared to alternative anesthetic agents.

Q: Are there any long-term studies about the effects of Suprane?

A: Official summaries of research evidence show that studies have primarily focused on immediate emergence and short-term recovery, with measurements often taken only in the hours following the procedure. Evidence demonstrating improved medium- and long-term quality of recovery analyses is not currently available.

How should Suprane be stored and disposed of?

How to Store and Dispose of Suprane (Desflurane)

The storage and disposal of Suprane must strictly adhere to the conditions documented in regulatory labeling to maintain product stability and ensure safety.


Required Storage Conditions

  • Temperature: Store the product between 15 C and 30 C (59 F to 86 F), and do not store under freezing conditions.
  • Container and Position: The container must be kept tightly closed and stored in the upright position in a dry, cool, and well-ventilated area.
  • Protection: The medicine must be kept out of the sight and reach of children.

Disposal and Handling

Disposal of unused product, residues, and the container must be carried out through an approved waste disposal plant in accordance with local and national regulations. Specific procedures for managing large spills require the material to be contained, absorbed, and placed in closed containers for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Suprane found in:

A-Z Index: